Lemtrada (alemtuzumab) under safety review by EMA
15 April 2019
The European medical regulatory body has announced a safety review of alemtuzumab (Lemtrada), an approved medication for relapsing
The European medical regulatory body has announced a safety review of alemtuzumab (Lemtrada), an approved medication for relapsing
Brain tissue can be split into two kinds, grey matter (mainly nerve cell bodies and branching connections) and
We met at an MS Research Australia engagement session as part of the exciting Stop and Reverse MS
Non-processed red meat consumption has been linked with reduced risk of MS according to a new study suggesting it may have a protective effect against developing MS.
New MS medication siponimod has received approval in the United States for use in people with relapsing forms of MS which includes active secondary progressive MS.
A new study has shown that early intensive treatment for MS gives better outcomes than starting on a moderately effective therapy and escalating to stronger medication.
Four of the 2019 awarded MS Research Australia grants focus on innovative ways to use MRI to better understand MS, rather than simply as a clinical tool.
MS Research Australia is pleased to be supporting several high calibre new research projects which focus on the link between diet and MS.
Despite having a similar core temperature to those without MS while resting and exercising, people with MS show a significantly reduced sweat response.